News & Updates
Filter by Specialty:
Booster dose effective in reducing COVID-19 across ages in adults
The risk of COVID-19 is substantially reduced in adults who receive a third “booster” dose of the BNT162b2 vaccine regardless of their age, according to a study from Israel.
Booster dose effective in reducing COVID-19 across ages in adults
23 Feb 2022
Post-MPI statin use prevents MACE in patients with elevated coronary artery calcium score
Use of moderate- to high-intensity statins (MHIS) after myocardial perfusion imaging (MPI) leads to significantly fewer major adverse cardiovascular events (MACE) and is an independent negative predictor for 24-months MACE among patients with normal MPI and coronary artery calcium (CAC) score >300, a Singapore study has shown.
Post-MPI statin use prevents MACE in patients with elevated coronary artery calcium score
23 Feb 2022
Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?
In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.
Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?
23 Feb 2022
Hypertension in pregnancy: Labetalol extends benefits for pregnancy outcomes
Common blood pressure (BP)-lowering medications in pregnancy cut the risk of severe hypertension, but labetalol has the added advantage of reducing the risks of proteinuria or pre-eclampsia and perinatal death, according to the results of a network meta-analysis.
Hypertension in pregnancy: Labetalol extends benefits for pregnancy outcomes
22 Feb 2022
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
Biologic disease-modifying antirheumatic drug (bDMARD) therapy is effective in reducing ankylosing spondylitis (AS) disease activity, reports a study, noting how treatment has persisted for up to 8 years among patients remaining on their first bDMARD, which is longer than on subsequent agents.
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
22 Feb 2022
NOACs preferable over warfarin in AF patients with bioprosthetic valves
Use of nonvitamin K oral anticoagulants (NOACs) results in a reduced incidence of thromboembolic events and major bleeding relative to warfarin in patients with atrial fibrillation (AF) and bioprosthetic valves or valve repair, suggests a study.
NOACs preferable over warfarin in AF patients with bioprosthetic valves
22 Feb 2022
Add-on lenacapavir helps maintain virologic suppression in treatment-naïve PWH
Combining the potent first-in-class capsid assembly inhibitor lenacapavir with other antiretroviral agents led to sustained high rates of virologic suppression in treatment-naïve persons with HIV-1 (PWH) infection, according to the week-54 results of the phase II Calibrate trial.
